HTG, Inc. has launched the quantitative nuclease protection assay (qNPA) 384/9 gene expression assay. This format enables the measurement of nine genes in a 384-well ArrayPlate and provides a higher plex, high-throughput screening and profiling method for accelerating drug discovery and development with molecular biomarkers.
This automated assay is based on HTG’s qNPA ArrayPlate technology platform, which allows researchers to investigate a larger, customized set of genes with greater precision than traditional high throughput screening assays. The technology allows pharmaceutical researchers who handle primary and secondary screening to quickly and efficiently measure gene expression levels of mRNA and miRNA in a wide variety of cell and tissue types.
This assay was created to accommodate the needs of researchers looking at different numbers of genes and needing a higher plex format to do so.
HTG’s qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology, and clinical development. HTG’s platform is highly flexible and automation-friendly; it allows scientists to test any sample, including fixed tissues, without RNA extraction or target amplification.
Published in Drug Discovery & Development magazine: Vol. 12, No. 6, June, 2009, p.34.
